Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
In this phase 2 study, we further explored the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-20094 in patients with type 2 diabetes mellitus (T2DM)
Common, typically benign symptoms include: Mild erythema (redness) at the injection site, usually less than 2 inches in diameter Slight swelling or a small raised area that feels firm to touch Transient tenderness or mild discomfort lasting 1 to 3 days Minimal itching without spreading or worsening Small bruising (ecchymosis) at the puncture site These reactions generally appear within minutes to hours after injection and typically resolve spontaneously within 2 to 4 days without treatment
PAI-1 modulation
Report persistent or severe symptoms to your prescriber right away
US$ 22.10
US$ 28.82
US$ 22.43
US$ 28.45
US$ 25.45
US$ 25.67
